You must have a short memory. They already did that last year. It didn't work. They have been trying to get decent financing for over a year. Remember the 3 trips to Monaco, International Fusion etc... All they could come up with was the floor-less convertibles. I stated in an earlier post what my expectation is for upfront money and milestone payments. This is a do or die situation for AMBS. They just need enough money to get them to initial data in the trial and appease the toxics in the meantime. I expect there will be a milestone payment with positive initial data.
If the deal doesn't put AMBS on good financial footing and a plan forward, then there is no reason for them to do it. That is why I am confident it will. Once there is positive data, ESS will be worth $100 million, at which time it would be easy for them to do an offering and raise money, so there is no reason for them to give away half of the asset today if they don't get something significant in return.
(4)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links